[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100295730":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":7,"acronym":7,"eligibilityCriteria":21,"healthyVolunteers":18,"sex":22,"minAge":23,"maxAge":7,"enrollmentInfo":24,"targetDuration":7,"studyType":27,"phases":7,"briefSummary":28,"conditions":29,"keywords":31,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":7},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Philippe Barthélémy, MD","CONTACT","33 3 88 11 58 77","philippe.barthelemy@chru-strasbourg.fr",{"type":15,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100295730","retrospective-study-in-patients-with-metastatic-renal-cancer-treated-with-tki-sequence-tyrosine-kinase-inhibitors-of-vegfr---mtor--axitinib-inhibitors-or-anti-vegf-antibody--inhibiteurs-mtor---axitinib-100295730",false,"NCT03129724","Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib","Inclusion criteria:\n\n* Patient with metastatic kidney cancer (all histological types)\n* Male or female aged (e) of 18 or more\n* Patient has been treated or under treatment with axitinib (Inlyta®) in the third line after the first line of targeted TKI therapy and after mTORi in 2nd line, or\n* Patient receiving the treatment sequence VEGFmAb - mTORi - axitinib For living patients: patient informed and having given oral consent\n\nExclusion criteria:\n\n* Patient who received more than one line of antiangiogenic therapy in the metastatic phase before initiation of treatment with axitinib (except patients in the study Pisces) Patient received a second line treatment with TKI Patient refused to participate in the study","ALL","18 Years",{"count":25,"type":26},100,"ESTIMATED","OBSERVATIONAL","Describe in patients with metastatic kidney cancer treatment modalities with the type sequences: TKI - mTORi - Axitinib or VEGF mAb - mTORi - Axitinib.",[30],"Kidney Neoplasms",[30,32,33,34,35,36,37],"Kidney","Neoplasms","TKI","Axitinib","VEGF","mTORi","UNKNOWN","2017-04-21",{"date":41,"type":42},"2017-04-26","ACTUAL",{"date":44,"type":7},"2016-09",{"date":46,"type":26},"2017-07",{"name":5,"class":6}]